[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-neoplasms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100594865","phase-4-fenofibrate-role-in-the-prophylaxis-from-peripheral-neuropathy-induced-by-bortezomib-lenalidomide-and-dexamethasone-vrd-protocol-in-the-treatment-of-patients-with-multiple-myeloma-mm-100594865",false,"NCT07025005","Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)","Clinical Study to Evaluate the Possible Role of Fenofibrate in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone Protocol in the Treatment of Patients With Multiple Myeloma","VRd MM Fibrate","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Newly diagnosed MM patients according to the revised International Myeloma Working Group Diagnostic Criteria for the diagnosis of Multiple Myeloma (IMWG).\n* Patients being treated by bortezomib-based VRd chemotherapy regimen.\n* Patients with performance status \\\u003C2 according to Eastern Cooperative Oncology Group (ECOG) score.\n* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL and hemoglobin level ≥ 10 g\u002Fdl).\n* Patients with adequate liver function (serum bilirubin \\\u003C 1.2 mg\u002Fdl) and adequate renal function (serum creatinine \\\u003C 1.5 mg\u002Fd).\n\nExclusion Criteria:\n\n* Patients with prior exposure to neurotoxic agents (Cis-platin, vincristine, taxanes, foscarnet, INH, etc..) in the last 6 months.\n* Concomitant use of antioxidant vitamins (vitamin A, C, E), anticonvulsants, tricyclic antidepressants, other medications used for neuropathic pain (gabapentin, lamotrigine, carbamazepine).\n* Preexisting peripheral neuropathy resulting from other causes such as diabetes and brain disorders, hypothyroidism, autoimmune diseases, hepatitis C.\n* Patients with inflammatory diseases (ulcerative colitis, rheumatoid arthritis).\n* Patients with conditions associated with oxidative stress (smoking, tuberculosis, comorbid obesity).\n* Patients with active liver disease (cirrhosis, fatty liver, hepatitis C, etc..).\n* Patients with myopathy.\n* Patients with other malignancies.\n* Patients with renal impairment, including those with end-stage renal disease and those receiving dialysis.\n* Patients with Gallbladder disease and gallstones.\n* Pregnant and breast-feeding women.\n* Patients with Known allergy to the fenofibrates.\n* Concurrent use of statin, colchicine, Ciprofibrate, idelalisib, enzyme inducers (phenytoin, phenobarbitone, carbamazepine,…), enzyme inhibitors (ketoconazole, clarithromycin,…), drugs with high plasma protein binding capacity (Sulfonamides, valproate, oral hypoglycemic, warfarin,…) to avoid potential pharmacodynamics and pharmacokinetic drug interactions.","ALL","18 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aims at evaluating the possible beneficial role of Fenofibrate in attenuating the peripheral neuropathy associated with bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen in newly diagnosed multiple myeloma patients.The study aims to asses VRd protocol induced peripheral neuropathy through:\n\n1. The implication of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) and The use of Neurotoxicity-12 items questionnaire score (Ntx-12) from the validated Functional Assessment of Cancer Therapy\u002FGynecologic Oncology Group \"FACT\u002FGOG-Ntx-12 for grading of neuropathy at baseline and by the end of every two VRd cycles.\n2. The assessment of biological markers:\n\nBrain -derived neurotrophic factor (BDNF) and Neuro-filament light chain (NfL). through comparing two groups: Group one: (Control group; n=22): which will receive 6 cycles of VRd regimen (each cycle will be given every 28 days).\n\nGroup two: (Fenofibrate group; n=22): which will receive the same regimen plus Fenofibrate 160 mg once daily.",[27,28],"Peripheral Neuropathy","Multiple Myeloma, Neoplasms",[30,31,32,33,34,35],"peripheral neuropathy","multiple myeloma","bortezomib induced peripheral neuropathy (BIPN)","Fenofibrate","VRd protocol","lenalidomide","RECRUITING","2025-11-01",{"date":39,"type":40},"2025-11-04","ACTUAL",{"date":42,"type":40},"2025-08-30",{"date":44,"type":21},"2026-09-30",{"name":46,"class":47},"Tanta University","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100585919","addressing-social-determinants-of-health-among-metro-detroit-cancer-survivors-100585919","NCT06908629","Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors","Addressing Social Determinants of Health (SDOH) Among Metro Detroit Cancer Survivors: A Pilot Feasibility Study (The Resource Ready Study)","Inclusion Criteria:\n\n* 18 years or older\n* past or current cancer diagnosis\n* reside in metropolitan Detroit (Wayne, Oakland, Macomb counties)\n* English proficient\n* Actively receiving care through one of Karmano's Cancer Institute's outpatient clinics OR post treatment survivors in the Detroit Research on Cancer Survivors (ROCS) longitudinal cohort study who have reported past food insecurity and agreed to be contacted for further research\n\nExclusion Criteria:\n\n* none",{"count":57,"type":21},120,[59],"NA","The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are:\n\n* Can we have a completion rate of at least 80% of participants filling out the screening tool?\n* Can we determine procedures for patient referrals based on social needs\n* Can we implement brief interventions based on food access and digital inclusion (ensuring everyone has access to the digital technologies they need to participate in society)",[62,63,64,65,28],"Cancer","Cancer Survivors","Gastrointestinal Cancers","Neuroendocrine Tumors","2025-08-25",{"date":68,"type":40},"2025-08-26",{"date":70,"type":40},"2024-09-03",{"date":72,"type":21},"2027-05",{"name":74,"class":47},"Barbara Ann Karmanos Cancer Institute",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100567391","5p15-9q22-15q22-hyperdiploidy-and-their-significance-in-multiple-myeloma-patients-100567391","NCT06667583","5p15\u002F 9q22\u002F 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients","Inclusion Criteria:\n\nNewly diagnosed Multiple Myeloma Patients -\n\nExclusion Criteria:\n\nPatient of Multiple Myeloma who received treatment\n\n\\-",{"count":83,"type":21},40,"OBSERVATIONAL","Our study aims to detect 5p15\u002F 9q22\u002F 15q22 hyperdiploidy and thier significance in Multiple Myeloma patients",[28],[88],"Hyperdiploidy","NOT_YET_RECRUITING","2024-10-30",{"date":92,"type":40},"2024-11-01",{"date":94,"type":21},"2024-12-01",{"date":96,"type":21},"2026-01-01",{"name":98,"class":47},"Assiut University"]